DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s32np9/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Cancer-Pipeline Insights" report to their offering.

Summary

Metastatic Renal Cell Cancer- Pipeline Insights provides the in-depth analysis of the pipeline assets across the Metastatic Renal Cell Cancer. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Metastatic Renal Cell Cancer Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Metastatic Renal Cell Cancer- Pipeline Insights Report covers the Metastatic Renal Cell Cancer pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Metastatic Renal Cell Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products.

Scope

• The report provides a Metastatic Renal Cell Cancer Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
• Coverage of the Metastatic Renal Cell Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
  

Key Topics Covered:

• Metastatic Renal Cell Cancer Overview
• Metastatic Renal Cell Cancer Pipeline Therapeutics
• Metastatic Renal Cell Cancer Therapeutics under Development by Companies
• Metastatic Renal Cell Cancer Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Metastatic Renal Cell Cancer Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Metastatic Renal Cell Cancer Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Metastatic Renal Cell Cancer Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Metastatic Renal Cell Cancer - Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Metastatic Renal Cell Cancer - Discontinued Products
• Metastatic Renal Cell Cancer - Dormant Products
• Companies Involved in Therapeutics Development for Metastatic Renal Cell Cancer
  

For more information visit http://www.researchandmarkets.com/research/s32np9/metastatic_renal

...